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Abstract: Adenoviruses (AdVs) are prevalent and give rise to chronic and recurrent disease. The human
AdV (HAdV) species B and C, such as HAdV-C2, C5 and B14, cause respiratory disease, and constitute
a health threat for immuno-compromised individuals. HAdV-Cs are well known for lysing cells, owing
to the E3 CR1-฀-encoded adenovirus death protein (ADP). We previously reported a high-throughput
image-based screening frame-work and identified an inhibitor of HAdV-C2 multi-round infection, Nelfi-
navir mesylate. Nelfinavir is the active ingredient of Viracept, an FDA-approved inhibitor of the human
immuno-deficiency virus (HIV) aspartyl protease, and used to treat acquired immuno-deficiency syndrome
(AIDS). It is not effective against single round HAdV infections. Here, we show that Nelfinavir inhibits
the lytic cell-free transmission of HAdV, indicated by the suppression of comet-shaped infection foci in
cell culture. Comet-shaped foci occur upon convection-based trans-mission of cell-free viral particles from
an infected cell to neighbouring uninfected cells. HAdV lacking ADP was insensitive to Nelfinavir, but
gave rise to comet-shaped foci indicating that ADP enhances but is not required for cell lysis. This was
supported by the notion that HAdV-B14 and B14p1 lacking ADP were highly sensitive to Nelfinavir,
although HAdV-A31, B3, B7, B11, B16, B21, D8, D30 or D37 were less sensitive. Conspicuously, Nel-
finavir unco-vered slow-growing round-shaped HAdV-C2 foci, independent of neutralizing antibodies in
the medium, indicative of non-lytic cell-to-cell transmission. Our study demonstrates the repurposing
potential of Nelfinavir with post-exposure efficacy against different HAdVs, and describes an alternative
non-lytic cell-to-cell transmission mode of HAdV.
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Adenoviruses (AdVs) are prevalent and give rise to chronic and recurrent disease. The 18 
human AdV (HAdV) species B and C, such as HAdV-C2, C5 and B14, cause respiratory 19 
disease, and constitute a health threat for immuno-compromised individuals. HAdV-Cs 20 
are well known for lysing cells, owing to the E3 CR1-β-encoded adenovirus death protein 21 
(ADP). We previously reported a high-throughput image-based screening framework and 22 
identified an inhibitor of HAdV-C2 multi-round infection, Nelfinavir mesylate. Nelfinavir is 23 
the active ingredient of Viracept, an FDA-approved inhibitor of the human immuno-24 
deficiency virus (HIV) aspartyl protease, and used to treat acquired immunodeficiency 25 
syndrome (AIDS). It is not effective against single round HAdV infections. Here, we show 26 
that Nelfinavir inhibits the lytic cell-free transmission of HAdV, indicated by the 27 
suppression of comet-shaped infection foci in cell culture. Comet-shaped foci occur 28 
upon convection-based transmission of cell-free viral particles from an infected cell to 29 
neighbouring uninfected cells. HAdV lacking ADP was insensitive to Nelfinavir, but gave 30 
rise to comet-shaped foci indicating that ADP enhances but is not required for cell lysis. 31 
This was supported by the notion that HAdV-B14 and B14p1 lacking ADP were highly 32 
sensitive to Nelfinavir, although HAdV-A31, B3, B7, B11, B16, B21, D8, D30 or D37 were 33 
less sensitive. Conspicuously, Nelfinavir uncovered slow-growing round-shaped HAdV-34 
C2 foci, independent of neutralizing antibodies in the medium, indicative of non-lytic cell-35 
to-cell transmission. Our study demonstrates the repurposing potential of Nelfinavir with 36 
post-exposure efficacy against different HAdVs, and describes an alternative non-lytic 37 
cell-to-cell transmission mode of HAdV. 38 
39 
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Adenovirus฀ (AdV)฀ was฀ first฀ described฀ in฀ 1953฀ by฀ Rowe฀ and฀ co-workers฀ as฀ a฀ cytopathologic฀42 
agent฀ isolated฀ from฀human฀adenoids฀ (1).฀More฀ than฀100฀human฀AdV฀(HAdV)฀genotypes฀have฀43 
since฀been฀characterized฀by฀molecular฀genetics฀or฀serology฀and฀grouped฀into฀seven฀species฀(2,฀44 
3).฀HAdV฀species฀A,฀F฀and฀G฀replicate฀in฀the฀gastrointestinal฀tract,฀B,฀C฀and฀E฀in฀the฀respiratory฀45 
organs,฀ and฀ B฀ and฀ D฀ in฀ conjunctival฀ cells฀ of฀ the฀ eyes.฀ Species฀ B฀ members฀ have฀ a฀ broad฀46 
tropism,฀including฀kidney฀and฀cells฀of฀the฀hematopoietic฀lineage฀(4–6).฀HAdV-caused฀illness฀can฀47 
range฀from฀asymptomatic฀to฀ lethal,฀especially฀ in฀ immunocompromised฀ individuals฀ (7–9).฀HAdV฀48 
outbreaks฀ are฀ frequent฀ in฀ military฀ training฀ camps,฀ but฀ also฀ nursing฀ homes,฀ as฀ recorded฀ in฀49 
recurrent฀outbreaks฀of฀HAdV-E4฀and฀HAdV-B7฀(5,฀10–13).฀To฀counter฀ the฀disease฀burden,฀an฀50 
oral฀HAdV-E4/B7฀ vaccine฀was฀ reintroduced,฀ leading฀ to฀ a฀ sharp฀ decline฀ in฀ adenoviral฀ disease฀51 
among฀ military฀ recruits฀ (5,฀ 14,฀ 15).฀ In฀ addition฀ to฀ recurrent฀ HAdV฀ outbreaks,฀ novel฀ HAdV฀52 
variants฀emerge,฀some฀of฀them฀causing฀pneumonia฀and฀death฀of฀elderly฀with฀chronic฀diseases.฀53 




AdV฀ as฀ gene฀ therapy฀ vectors฀ (27)฀ as฀ well฀ as฀ oncolytic฀ viruses฀ (28,฀ 29)฀ no฀ FDA-approved฀58 
specific฀ anti-HAdV฀ treatment฀ is฀ available฀ to฀ date.฀ Clinically,฀ HAdV฀ infections฀ are฀ treated฀with฀59 
Ribavirin,฀Cidofovir,฀ or฀more฀ recently,฀Brincidofovir,฀which฀ all฀ inhibit฀ viral฀DNA฀ replication฀ (30,฀60 
31).฀61 
฀62 




to฀ the฀ coxsackievirus฀ adenovirus฀ receptor฀ (CAR)฀ and฀ integrin฀ co-receptors,฀ followed฀ by฀67 
receptor-mediated฀endocytosis,฀endosomal฀ lysis฀and฀microtubule-motor฀driven฀ transport฀ to฀ the฀68 
nucleus,฀where฀it฀uncoats฀DNA฀and฀delivers฀the฀DNA฀into฀the฀nucleus฀(38,฀51–62).฀The฀first฀viral฀69 
protein฀ expressed฀ is฀ E1A,฀ a฀ multifunctional฀ intrinsically฀ disordered฀ protein฀ controlling฀ the฀70 
transcriptional฀activity฀of฀all฀AdVs,฀as฀well฀as฀many฀cellular฀promoters,฀thereby฀affecting฀the฀cell฀71 
cycle,฀ differentiation,฀ transformation฀ and฀ apoptosis฀ (63–68).฀ Viral฀ early฀ proteins฀ besides฀ E1A฀72 
mediate฀immune฀escape,฀block฀activation฀of฀pro-apoptotic฀pathways฀and฀form฀nuclear฀viral฀DNA฀73 
replication฀ compartments.฀ Late฀ viral฀ proteins฀ give฀ rise฀ to฀mature฀ progeny฀ virions฀ upon฀ limited฀74 
proteolysis฀ of฀ capsid฀ proteins฀ by฀ the฀ viral฀ cysteine฀ protease฀ L3/p23฀ (69–71).฀ Mature฀ HAdV฀75 
progeny฀ is฀ released฀ upon฀ rupture฀ of฀ the฀ nuclear฀ envelope฀ and฀ plasma฀ membrane,฀ which฀76 
facilitates฀rapid฀viral฀dissemination฀and฀plaque฀formation฀in vitro฀(72–74).฀The฀convection฀forces฀77 
in฀the฀medium฀give฀rise฀to฀comet-shaped฀infection฀foci฀in฀cell฀cultures฀(72).฀Foci฀of฀infected฀cells฀78 
are฀ also฀ found฀ in฀ tissue,฀ such฀ as฀ rat฀ liver฀ upon฀ intravenous฀ inoculation฀ of฀ HAdV-C5฀ (75).฀79 
Accordingly,฀acute฀HAdV฀ infections฀ trigger฀an฀ inflammatory฀ response,฀as฀shown฀ in฀airways฀or฀80 













































The฀ mechanisms฀ of฀ virus฀ transmission฀ are฀ highly฀ virus-specific.฀ They฀ comprise฀ non-lytic฀84 
pathways฀ involving฀ the฀ secretory-endocytic฀ circuits,฀ multi-vesicular฀ or฀ autophagic฀ membrane฀85 
processes,฀ cellular฀ protrusions,฀ or฀ transient฀ breaches฀ of฀ membrane฀ integrity฀ (80–84).฀ In฀86 
contrast,฀lytic฀egress฀pathways฀further฀involve฀the฀destabilization฀of฀cellular฀membranes฀by฀viral฀87 
and฀host฀factors,฀often฀tuned฀by฀the฀cytoskeleton฀(37,฀85–88).฀HAdV-C2฀controls฀lytic฀cell฀death฀88 
by฀ the฀adenovirus฀death฀protein฀ (ADP),฀also฀known฀as฀11.6K,฀as฀concluded฀ from฀genetic฀and฀89 
overexpression฀studies฀(73,฀74).฀ADP฀is฀a฀type฀III฀membrane฀protein฀transcribed฀from฀the฀CR1-β 90 
region฀ in฀ the฀ immuno-regulatory฀ E3a฀ locus.฀ All฀ HAdV-C฀ members฀ harbour฀ homologous฀ E3a฀91 
CR1-β฀ sequences฀ (e.g.฀ 10.5K฀ in฀ HAdV-C5).฀ Other฀ HAdV฀ species฀ differ฀ in฀ their฀ E3฀ region,฀92 










mostly฀ clinical฀ or฀ preclinical฀ compounds฀ (100,฀ 101).฀ Nelfinavir฀ is฀ the฀ off-patent฀ active฀103 
pharmaceutical฀ ingredient฀ of฀ Viracept,฀ FDA-approved,฀ which฀ inhibits฀ the฀ human฀ immuno-104 
deficiency฀ virus฀ (HIV)฀ protease฀ (102).฀ The฀work฀ here฀ documents฀ the฀ repurposing฀ potential฀ of฀105 
Nelfinavir,฀ which฀ is฀ effective฀ against฀ a฀ spectrum฀ of฀ HAdV฀ types฀ in฀ a฀ post฀ exposure฀manner.฀106 
Nelfinavir฀is฀partly,฀but฀not฀exclusively,฀active฀against฀ADP-encoding฀HAdV฀types,฀and฀uncovers฀107 

















































harbouring฀ the฀ enhanced฀ green฀ fluorescent฀ protein฀ (GFP)฀ under฀ a฀ constitutively฀ active฀115 
cytomegalovirus฀ (CMV)฀ promoter.฀ It฀ was฀ grown฀ in฀ A549฀ cells฀ and฀ purified฀ by฀ double฀ CsCl฀116 
gradient฀centrifugation฀(103).฀Aliquots฀supplemented฀with฀10%฀(v฀/฀v)฀glycerol฀were฀stored฀at฀ -117 
80°C.฀HAdV-C2-dE3B-GFP฀was฀ found฀ to฀be฀homogeneous฀by฀SDS-PAGE฀and฀negative-stain฀118 
analyses฀ in฀ transmission฀electron฀microscopy฀ (EM).฀Recombinant฀HAdV-C2-dE3B-GFP-dADP฀119 
was฀ generated฀ using฀ homologous฀ recombination฀ according฀ to฀ the฀ Warming฀ recombineering฀120 









the฀ late฀ Thomas฀ Adrian฀ (Hannover฀ Medical฀ School,฀ Germany)฀ and฀ were฀ verified฀ by฀ DNA฀130 
restriction฀analysis฀ (108,฀109).฀HAdV฀types฀B14฀(19,฀20)฀and฀B21a,฀ isolate฀LRTI-6฀(110)฀were฀131 
kindly฀provided฀by฀Albert฀Heim฀(Hannover฀Medical฀School,฀Germany).฀HAdV-B3-pIX-FS2A-GFP฀132 
and฀B35-pIX-FS2A-GFP฀contain฀an฀enhanced฀GFP฀open฀reading฀frame฀(ORF)฀genetically฀fused฀133 
to฀ the฀downstream฀end฀of฀ the฀HAdV฀pIX฀gene฀using฀an฀autocleavage฀FS2A฀sequence฀ (111–134 
113).฀ rec700฀ (114)฀and฀dl712฀ (115)฀were฀obtained฀ from฀William฀Wold฀ (Saint-Louis฀University,฀135 
Saint-Louis,฀USA).฀rec700฀is฀a฀recombinant฀HAdV-C5฀containing฀C2฀sequences฀from฀nucleotide฀136 
-236฀to฀2437฀of฀the฀E3฀transcription฀unit,฀and฀comprises฀the฀C2฀E3a฀ORFs฀12.5K,฀6.7K,฀19K฀and฀137 
ADP,฀ as฀well฀ as฀major฀ parts฀ of฀ the฀E3b฀ORF฀RIDα฀ (10.4K฀ protein)฀ (116).฀Mouse฀ adenovirus฀138 
(MAdV)-1-pIX-FS2A-GFP฀ and฀ MAdV-3-pIX-FS2A-GFP฀ were฀ constructed฀ as฀ described฀ (117,฀139 
118).฀ HAdV-C2฀ and฀ C5฀ were฀ obtained฀ from฀ Maarit฀ Suomalainen฀ (University฀ of฀ Zurich,฀140 






Cell lines 147 
A549฀ (human฀ adenocarcinomic฀ alveolar฀ basal฀ epithelium,฀ CCL-185),฀ HeLa฀ (human฀ epithelial฀148 
cervix฀ carcinoma,฀ CCL-2)฀ and฀ HBEC฀ (HBEC3-KT,฀ normal฀ human฀ bronchial฀ epithelium,฀ CRL-149 
4051)฀cells฀were฀obtained฀from฀the฀American฀Type฀Culture฀Collection฀(ATCC,฀Manassas,฀USA).฀150 
HCE฀ (normal฀ human฀ corneal฀ epithelium)฀ cells฀ were฀ obtained฀ from฀ Karl฀ Matter฀ (University฀151 











































Compton,฀ Yale฀ School฀ of฀ Medicine,฀ USA.฀ A549,฀ HeLa,฀ HCE฀ and฀ CMT-93฀ cell฀ cultures฀ were฀153 
maintained฀in฀high฀glucose฀DMEM฀(Thermo฀Fisher฀Scientific,฀Waltham,฀USA)฀containing฀7.5%฀(v฀154 
/฀ v)฀FCS฀ (Invitrogen,฀Carlsbad,฀USA),฀1%฀ (v฀ /฀ v)฀ L-glutamine฀ (Sigma-Aldrich,฀St.฀ Louis,฀USA)฀155 
and฀1%฀(v฀/฀v)฀penicillin฀streptomycin฀(Sigma-Aldrich,฀St.฀Louis,฀USA)฀and฀subcultured฀following฀156 
phosphate-buffered฀saline฀(PBS)฀washing฀and฀trypsinisation฀(Trypsin-EDTA,฀Sigma-Aldrich,฀St.฀157 
Louis,฀ USA)฀ bi-weekly.฀ HBEC฀ cells฀ were฀ maintained฀ in฀ endothelial-basal฀ medium฀ (ATCC,฀158 





Nelfinavir฀mesylate฀ (CAS฀number฀159989-65-8)฀powder฀was฀obtained฀ from฀MedChemExpress฀164 




Cellular impedance measurement 169 
Impedance-based฀ assays฀ were฀ performed฀ using฀ the฀ xCELLigence฀ system฀ (Roche฀ Applied฀170 
Science฀ and฀ ACEA฀ Biosciences)฀ as฀ described฀ previously฀ (122,฀ 123)฀ according฀ to฀ the฀171 
manufacturer’s฀ instructions฀ (124)฀ in฀cell฀culture฀environment฀(37°C,฀5%฀CO2,฀95%฀humidity)฀ in฀172 
duplicates.฀ The฀ 16-well฀ E฀ plates฀ have฀ a฀ gold-plated฀ sensor฀ array฀ embedded฀ in฀ their฀ glass฀173 
bottom฀by฀which฀the฀electrical฀impedance฀across฀each฀well฀bottom฀is฀measured.฀The฀impedance฀174 
per฀well,฀ termed฀ cell฀ index฀ (CI),฀ is฀ recorded฀as฀a฀dimensionless฀quantity.฀The฀background฀CI฀175 




For฀ the฀quantification฀of฀Nelfinavir฀ toxicity,฀50฀µl฀ of฀ supernatant฀were฀ removed฀18฀h฀ later฀and฀180 
replaced฀ by฀ 2-fold฀ concentrated฀ Nelfinavir฀ or฀ DMSO฀ solvent฀ as฀ the฀ control฀ dilution฀ in฀181 
supplemented฀medium฀(final฀Nelfinavir฀concentration฀0.4-100฀µM฀ in฀100฀µl฀ /฀well).฀The฀control฀182 
was฀supplemented฀medium.฀Impedance฀was฀recorded฀every฀15฀min฀over฀5฀days.฀TC50฀indicates฀183 
the฀ concentration฀ of฀ Nelfinavir,฀ which฀ caused฀ 50%฀ impedance฀ reduction฀ compared฀ to฀ the฀184 
solvent-treated฀ cells.฀ TC50฀ was฀ calculated฀ by฀ non-linear฀ regression฀ of฀ solvent-normalized฀ CI฀185 
over฀the฀concentration฀of฀Nelfinavir.฀฀186 
฀187 
For฀ the฀ quantification฀ of฀ Nelfinavir฀ effects฀ on฀ the฀ cytopathogenicity฀ of฀ HAdV-C2-dE3B-GFP฀188 
compared฀to฀HAdV-C2-dE3B-GFP-dADP฀infection,฀50฀µl฀supernatant฀were฀removed฀18฀h฀ later฀189 
and฀ replaced฀with฀Nelfinavir-฀ and฀ virus-supplemented฀medium.฀25฀µl฀ of฀ a฀ 4-fold฀ concentrated฀190 
Nelfinavir฀(final฀concentration฀0.4-100฀µM)฀or฀corresponding฀DMSO฀solvent฀control฀dilution฀(final฀191 
concentration฀1%)฀in฀supplemented฀medium฀or฀supplemented฀medium฀only฀were฀added฀to฀50฀µl฀192 
medium฀containing฀ cells.฀Additionally,฀ 25฀µl฀ of฀ a฀ 4-fold฀ concentrated฀virus฀ stock฀dilution฀were฀193 
added฀ (final฀ inoculum฀1.68*106฀ viral฀ particle(s)฀ (VP)฀ /฀well฀ HAdV-C2-dE3B-GFP฀and฀ 2.68*106฀194 











































delay฀ of฀ infection-induced฀ cytotoxicity฀ was฀ calculated฀ as฀ time฀ point฀ at฀ which฀ the฀ CI฀ of฀ the฀196 









to฀ 5฀ to฀ 50฀ plaques฀ per฀ 96-well.฀ 50฀ µl฀ Nelfinavir฀ to฀ obtain฀ 0.1฀ to฀ 50฀ µM฀ final฀ concentration฀ or฀206 
DMSO฀solvent฀control฀was฀also฀added,฀both฀in฀supplemented฀medium.฀For฀each฀experiment,฀a฀207 
non-infected,฀ treated฀ control฀ was฀ performed.฀ For฀ uphill฀ plaque฀ assays,฀ medium฀ volume฀ was฀208 
increased฀ to฀ 150฀ µl฀ with฀ identical฀ virus฀ and฀ drug฀ concentrations.฀ For฀ wash-in฀ /฀ wash-out฀209 
experiments,฀virus฀was฀ incubated฀on฀ the฀cells฀ in฀supplemented฀medium฀for฀1฀h฀at฀37°C,฀cells฀210 








BSA฀ in฀PBS.฀Cells฀were฀ incubated฀with฀381.7฀ng฀ /฀ml฀mouse฀α-HAdV฀hexon฀protein฀antibody฀219 
(Mab8052,฀Sigma-Aldrich,฀St.฀ Louis,฀USA)฀ and฀ subsequently฀ stained฀ using฀ 2฀ µg฀ /฀ml฀ goat฀ α-220 
mouse-AlexaFluor594฀ (A21203฀ or฀ A32742,฀ Thermo฀ Fisher฀ Scientific,฀Waltham,฀ USA).฀ Plates฀221 
were฀ imaged฀ on฀ either฀ an฀ IXM-XL฀ or฀ IXM-C฀ automated฀ high-throughput฀ fluorescence฀ micro-222 




Therapeutic index measurement 227 
The฀ infection฀ phenotype฀ for฀ each฀well฀ was฀ quantified฀ using฀ Plaque2.0฀ (101).฀ The฀ number฀ of฀228 
plaques฀was฀determined฀based฀on฀the฀infection฀signal฀(viral฀GFP฀or฀hexon฀immunofluorescence฀229 
staining).฀ Nuclei฀ stained฀ with฀ Hoechst฀ were฀ segmented฀ by฀ CellProfiler฀ (125).฀ Infected฀ nuclei฀230 
were฀ classified฀ based฀ on฀ the฀ median฀ infection฀ signal฀ per฀ nucleus฀ in฀ CellProfiler.฀ Data฀ were฀231 
plotted฀and฀EC50฀ (infected฀and฀ treated฀cells),฀TC50฀ (non-infected,฀ treated฀cells),฀as฀well฀as฀ the฀232 

















































quadruplicates,฀ as฀ described฀ under฀ Microscopic฀ plaque฀ assay.฀ Single฀ nuclei฀ (Hoechst)฀ were฀240 
segmented฀ using฀ CellProfiler฀ (125).฀ Median฀ GFP฀ and฀ hexon฀ signals฀ per฀ nucleus฀ were฀241 
measured,฀and฀ infected฀nuclei฀classified฀using฀the฀median฀GFP฀or฀hexon฀signals฀per฀nucleus.฀242 
Subsequently,฀ mean฀ and฀ standard฀ deviation฀ (SD)฀ over฀ all฀ infected฀ nuclei฀ per฀ well฀ were฀243 
calculated฀ in฀R฀version฀3.3.2฀ (126).฀Data฀were฀plotted฀ in฀GraphPad฀ (GraphPad฀Software,฀ Inc,฀244 
version฀8.1.2).฀245 
฀246 




and฀ fixed฀at฀4°C฀ in฀0.1฀M฀ ice-cold฀cacodylate฀buffer฀ (pH฀7.4),฀supplemented฀with฀2.5%฀(v฀ /฀v)฀251 
glutaraldehyde฀and฀0.5฀mg฀/฀ml฀ruthenium฀red฀for฀1฀h.฀Cells฀were฀washed฀with฀0.1฀M฀cacodylate฀252 
buffer฀ (pH฀7.4)฀ and฀post-fixed฀at฀RT฀ in฀0.05฀M฀cacodylate฀buffer฀ (pH฀7.4)฀ supplemented฀with฀253 
0.5%฀ (v฀ /฀ v)฀ OsO4฀ and฀ 0.25฀ mg฀ /฀ ml฀ ruthenium฀ red฀ for฀ 1฀ h.฀ Following฀ washing฀ with฀ 0.1฀ M฀254 
cacodylate฀buffer฀(pH฀7.36)฀and฀H2O,฀the฀samples฀were฀incubated฀in฀2%฀(v฀/฀v)฀uranyl฀acetate฀at฀255 




HAdV-C5 virus production in presence of Nelfinavir 260 
HAdV-C5฀was฀amplified฀ in฀ the฀medium฀containing฀0,฀1.25฀or฀3฀µM฀Nelfinavir฀ for฀4฀days.฀Cells฀261 
were฀harvested฀and฀disrupted฀by฀ three฀ freeze฀ /฀ thaw฀cycles.฀The฀cell฀debris฀was฀ removed฀by฀262 
Freon฀ extraction฀ and฀mature฀ full฀ HAdV฀ virions฀ were฀ purified฀ by฀ two฀ rounds฀ of฀ CsCl฀ gradient฀263 




Negative staining electron microscopy  268 
Double฀CsCl฀gradient-purified฀HAdV฀particles฀were฀adhered฀ to฀Collodion฀and฀2%฀ (v฀ /฀ v)฀amyl฀269 
acetate฀film-covered฀grids฀(300฀mesh฀Formvar/carbon-supported฀copper฀support฀films,฀Electron฀270 
Microscopy฀ Sciences,฀ Hatfield,฀ USA).฀ Viral฀ particles฀ were฀ negatively฀ stained฀ with฀ 2%฀ (v฀ /฀ v)฀271 
uranyl฀ acetate฀ and฀ viewed฀ on฀ a฀ transmission฀ electron฀ microscope฀ (Philips฀ CM100,฀ Philips,฀272 
Amsterdam,฀ Netherlands)฀ at฀ 100฀ kV.฀ Images฀ were฀ acquired฀ using฀ a฀ CCD฀ camera฀ (Orius฀273 
SC1000฀with฀4,000฀x฀2,600฀pixels,฀Gatan,฀Pleasanton,฀USA).฀฀274 
฀275 
Western blot analysis of HAdV protease activity 276 
















































ECL฀ Prime฀ Western฀ Blotting฀ Detection฀ Reagent฀ (GE฀ Health฀ Care,฀ Pittsburgh,฀ USA).฀ The฀283 
membranes฀ were฀ luminescence฀ imaged฀ on฀ an฀ Amersham฀ Imager฀ 680฀ (GE฀ Health฀ Care,฀284 
Pittsburgh,฀USA). 285 
฀286 








projections฀ were฀ calculated.฀ Image฀ analysis฀ was฀ performed฀ using฀ CellProfiler฀ (125).฀ Nuclei฀295 













α-hexon฀ (developed฀ by฀ Laurence฀ Fayadat฀ and฀ Wiebe฀ Olijve,฀ obtained฀ from฀ Developmental฀309 
Studies฀Hybridoma฀Bank฀developed฀under฀the฀auspices฀of฀the฀National฀Institute฀of฀Child฀Health฀310 
and฀Human฀Development฀and฀maintained฀by฀the฀University฀of฀Iowa,฀Iowa฀City,฀USA)฀(129)฀and฀311 
goat฀ α-mouse฀ AlexaFluor488฀ (A11029,฀ Thermo฀ Fisher฀ Scientific,฀Waltham,฀ USA).฀ Total฀ area฀312 





Assessment of HAdV infectivity of HAdV-C5±Nelfinavir 318 
Fifteen฀thousand฀A549฀cells฀were฀seeded฀per฀96-well฀in฀full฀DMEM฀and฀allowed฀to฀attach฀over฀319 
night฀ at฀ standard฀ cell฀ culture฀ conditions.฀ The฀ next฀ day,฀ the฀medium฀was฀ replaced฀ by฀ double฀320 
CsCl-purified฀HAdV-C5±Nelfinavir฀virus฀stocks฀at฀50฀ to฀0.001฀pg฀ /฀well฀of฀BCA-based฀viral฀protein฀321 
concentration฀ and฀ incubated฀ at฀ standard฀ cell฀ culture฀ conditions.฀ Cells฀ were฀ fixed฀ at฀ 52฀ hpi,฀322 











































Image-based฀ plaque฀ assay.฀ Images฀ were฀ quantified฀ using฀ Plaque2.0฀ (101).฀ Nuclei฀ were฀324 
segmented฀ based฀ on฀ Hoechst฀ signal.฀ Infected฀ cells฀ were฀ segmented฀ based฀ on฀ hexon฀325 
immunofluorescence฀staining฀signal.฀326 
฀327 
Egress assay 328 
A549฀ cells฀ were฀ seeded฀ at฀ 480,000฀ cells฀ per฀ 6-well฀ in฀ full฀ DMEM฀ and฀ infected฀ at฀ 1,100฀ pfu฀329 
HAdV-C2-dE3B-GFP฀per฀well฀the฀next฀day.฀Following฀1฀h฀of฀warm฀incubation,฀the฀supernatant฀330 
was฀removed,฀and฀cells฀were฀washed฀with฀PBS฀and฀detached฀by฀trypsin฀digestion.฀Infected฀cells฀331 
were฀ centrifuged฀ and฀ resuspended฀ in฀ fresh฀medium฀ to฀ remove฀ any฀ unbound฀ input฀ virus฀ and฀332 
seeded฀at฀180,000฀cells฀/฀12-well฀in฀medium฀supplemented฀with฀1.25,฀3฀or฀10฀µM฀Nelfinavir฀or฀333 
equivalent฀ amounts฀ of฀ DMSO฀ solvent฀ control.฀ At฀ the฀ indicated฀ times฀ pi,฀ the฀ supernatant฀was฀334 
harvested฀ and฀ cleared฀ by฀ centrifugation.฀ 200฀ µl฀ PBS฀ /฀ well฀ was฀ added฀ to฀ the฀ infected฀335 
monolayer.฀ Cells฀ were฀ disrupted฀ by฀ three฀ freeze฀ /฀ thaw฀ cycles฀ and฀ freon฀ extraction฀ was฀336 






Quantification of infectious progeny production 343 
Four฀hundred฀and฀eighty฀thousand฀A549฀cells฀were฀seeded฀per฀6-well฀dish฀and฀inoculated฀with฀344 
1,100฀pfu฀HAdV-C2-dE3B-GFP฀/฀well฀for฀1฀h฀at฀37°C,฀washed฀with฀PBS฀and฀detached฀by฀trypsin฀345 
digestion.฀ Infected฀ cells฀ were฀ centrifuged฀ and฀ resuspended฀ in฀ fresh฀ medium฀ to฀ remove฀ any฀346 
unbound฀input฀virus.฀Cells฀were฀seeded฀at฀180,000฀cells฀/฀12-well฀in฀medium฀supplemented฀with฀347 
1.25,฀ 3฀ or฀ 10฀µM฀Nelfinavir฀ or฀ the฀ respective฀DMSO฀solvent฀ control.฀Viral฀ progeny฀ in฀ the฀ cell฀348 
monolayer฀and฀supernatant฀was฀harvested฀at฀the฀indicated฀time฀pi฀by฀three฀freeze฀/฀thaw฀cycles.฀349 
The฀lysates฀were฀cleared฀by฀centrifugation฀and฀stored฀at฀4°C฀until฀titration฀on฀naive฀A549฀cells.฀350 
PFA-fixed,฀ Hoechst-stained฀ cells฀ were฀ imaged฀ at฀ 44฀ hpi฀ using฀ a฀ 4x฀ objective฀ on฀ an฀351 
epifluorescence฀IXM-XL฀(Molecular฀Devices,฀San฀Jose,฀USA).฀GFP-positive฀infected฀cells฀were฀352 
classified฀ based฀ on฀ median฀ nuclear฀ GFP฀ intensity฀ using฀ automated฀ image฀ analysis฀ by฀353 
CellProfiler฀(125).฀The฀yield฀per฀12-well฀was฀extrapolated฀by฀linear฀regression฀of฀the฀number฀of฀354 
infected฀cells฀per฀µl฀of฀harvested฀whole฀well฀ lysate฀using฀GraphPad฀(GraphPad฀Software,฀ Inc,฀355 
version฀8.1.2).฀356 
฀357 
Quantification of the antiviral potency of Nelfinavir 358 
Infection฀was฀performed฀as฀described฀under฀Microscopic฀ plaque฀assay.฀Cells฀were฀ incubated฀359 
with฀an฀ inoculum฀ranging฀between฀10฀ -฀2,560฀pfu฀ /฀well฀HAdV-C2-dE3B-GFP฀for฀1฀h฀at฀37°C.฀360 
Cells฀were฀washed฀with฀PBS฀and฀100฀µl฀DMEM฀phenol-free฀medium฀(Thermo฀Fisher฀Scientific,฀361 
Waltham,฀USA),฀supplemented฀with฀1%฀penicillin฀streptomycin฀(Sigma-Aldrich,฀St.฀Louis,฀USA),฀362 
1%฀ L-glutamine฀ (Sigma-Aldrich,฀ St.฀ Louis,฀ USA),฀ 7.5%฀ FBS฀ (Invitrogen,฀ Carlsbad฀ USA),฀ 1%฀363 
non-essential฀ amino฀ acids฀ (Sigma-Aldrich,฀ St.฀ Louis,฀ USA),฀ 1%฀ 100฀ mM฀ sodium฀ pyruvate฀364 












































imaged฀ at฀ the฀ indicated฀ times฀ pi฀ on฀ an฀ IXM-C฀ automated฀ high-throughput฀ fluorescence฀367 
microscope฀ (Molecular฀Devices,฀San฀Jose,฀USA)฀using฀a฀40x฀objective฀ (NA฀0.95)฀at฀ confocal฀368 




Morphological plaque characterization 373 
Plaques฀were฀segmented฀ in฀Plaque2.0฀ (101)฀and฀plaque฀region฀eccentricity฀was฀measured฀as฀374 
fraction฀of฀the฀distance฀between฀the฀two฀focal฀points฀of฀the฀ellipse฀divided฀by฀the฀length฀of฀the฀375 
major฀ axis.฀ Only฀ plaque฀ regions฀ consisting฀ of฀ at฀ least฀ five฀ infected฀ cells฀ (≥6,000฀px2)฀ with฀ a฀376 
centroid฀located฀600฀px฀from฀the฀well฀rim฀were฀considered฀to฀exclude฀spatial฀limitations.฀Plaque฀377 




Confocal microscopy of ADP localization 382 
Infection฀ and฀ immunofluorescence฀ stainings฀were฀ performed฀ as฀ described฀ under฀ Microscopic฀383 
plaque฀assay฀with฀a฀cell฀seeding฀density฀of฀3,000฀cells฀/฀well.฀Cells฀were฀incubated฀with฀1:1,000฀384 
rabbit฀ α-HAdV-C2-ADP87-101฀ antibody฀ (107)฀ and฀ subsequently฀ stained฀ using฀ donkey฀ α-rabbit-385 
AlexaFluor594฀(21207,฀Thermo฀Fisher฀Scientific,฀Waltham,฀USA)฀and฀0.2฀µg/ml฀NHS฀ester฀(Life฀386 
Technologies,฀ Carlsbad,฀ USA)฀ for฀ whole฀ cell฀ outline.฀ Plates฀ were฀ imaged฀ on฀ an฀ IXM-C฀387 
automated฀high-throughput฀fluorescence฀microscope฀(Molecular฀Devices,฀San฀Jose,฀USA)฀using฀388 









per฀ infected฀cell฀were฀normalized฀by฀ the฀according฀mean฀over฀all฀ infected฀cells฀of฀ the฀solvent฀398 
control.฀ Data฀ processing฀ was฀ performed฀ in฀ R฀ version฀ 3.3.2฀ (126).฀ Statistical฀ analysis฀ was฀399 
performed฀ in฀ GraphPad฀ (GraphPad฀ Software,฀ Inc,฀ version฀ 8.1.2)฀ using฀ the฀ non-parametric฀400 
Kolmogorov-Smirnov฀test.฀฀401 
฀402 
Western blot analysis of ADP processing 403 













































placed฀ on฀ ice฀ and฀ the฀ supernatant฀was฀ removed.฀ The฀ cells฀were฀washed฀ twice฀with฀ ice-cold฀407 
PBS.฀Cells฀were฀lysed฀in฀100฀µl฀COS฀lysis฀buffer฀(20฀mM฀Tris-HCl฀pH฀7.4,฀100฀mM฀NaCl,฀1฀mM฀408 
EDTA,฀1%฀Triton฀X-100,฀1฀mM฀DTT,฀25฀mM฀β-Glycerophosphate฀disodium,฀25฀mM฀NaF,฀1฀mM฀409 
Na3VO4,฀ 1x฀ protease฀ inhibitors฀ (Mini฀ Complete,฀ Roche,฀ Basel,฀ Switzerland)฀ for฀ 5฀min฀ on฀ ice.฀410 
Supernatant฀and฀washing฀PBS฀were฀collected฀and฀cells฀pelleted฀by฀centrifugation฀at฀16,000฀xg฀411 
for฀5฀min฀at฀4°C.฀Lysates฀were฀scraped฀off฀and฀used฀to฀resuspend฀the฀pelleted฀cells.฀Following฀412 
another฀ centrifugation,฀ the฀ supernatant฀ was฀ collected฀ and฀ stored฀ at฀ -20°C.฀ Samples฀ of฀ 15฀ µl฀413 
lysate฀were฀supplemented฀with฀SDS-containing฀loading฀buffer฀(0.35฀M฀Tris-HCl฀pH฀6.8,฀0.28%฀414 
SDS,฀30฀g฀/฀l฀DTT,฀0.6฀g฀/฀l฀bromophenol฀blue).฀Samples฀were฀denatured฀at฀95°C฀for฀5฀min฀and฀415 
proteins฀were฀separated฀on฀a฀denaturing฀15%฀acrylamide฀gel.฀Proteins฀ transferred฀ to฀ a฀PVDF฀416 
membrane฀were฀detected฀with฀1:1,000฀of฀a฀rabbit฀α-HAdV-C2฀ADP78-93฀antibody฀(107)฀followed฀417 
by฀ goat฀α-rabbit-HRP฀ (7074,฀ Cell฀ Signaling฀ Technology,฀Danvers,฀ USA).฀ Protein฀ bands฀were฀418 
visualized฀using฀ECL฀Prime฀Western฀Blotting฀Detection฀Reagent฀ (GE฀Health฀Care,฀Pittsburgh,฀419 
USA)฀ and฀ luminescence฀ imaged฀ on฀ an฀ Amersham฀ Imager฀ 680฀ (GE฀Health฀ Care,฀ Pittsburgh,฀420 
USA).฀421 
฀422 
Neutralization of HAdV cell-free progeny 423 
A549฀cells฀were฀seeded฀at฀15,000฀cells฀per฀well฀of฀a฀96-well-plate,฀incubated฀o/n฀and฀inoculated฀424 
with฀HAdV-C2-dE3B-GFP฀at฀34฀pfu฀ /฀well฀ for฀1฀h฀at฀37°C.฀Virus฀was฀ removed฀and฀cells฀were฀425 
washed฀with฀PBS,฀before฀0.25฀ng฀/฀ml฀Hoechst฀(Sigma-Aldrich,฀St.฀Louis,฀USA)-supplemented฀426 
DMEM฀ medium฀ containing฀ 1:12฀ HAdV-C2/5-neutralizing฀ dog฀ serum,฀ kindly฀ supplied฀ by฀ Anja฀427 
Ehrhardt,฀University฀Witten/Herdecke,฀Germany฀ (130),฀supplemented฀with฀40%฀v฀ /฀v฀glycerol),฀428 




Crystal violet-stained plaques 433 
Plaque฀ shapes฀ were฀ also฀ assessed฀ by฀ conventional฀ crystal฀ violet-stained฀ plaque฀ assay,฀434 
performed฀in฀A549฀cells฀in฀liquid฀supplemented฀DMEM฀medium.฀All฀infections฀were฀performed฀at฀435 
37°C,฀ 95%฀ humidity฀ and฀ 5%฀CO2฀ atmosphere.฀ At฀ the฀ indicated฀ time฀ pi,฀ cells฀ were฀ fixed฀ and฀436 
stained฀ for฀ 60฀min฀with฀PBS฀ solution฀ containing฀ 3฀mg฀ /฀ml฀ crystal฀ violet฀ and฀ 4%฀PFA฀ added฀437 


















































was฀ conducted฀ in฀ adenocarcinomic฀ human฀ alveolar฀ basal฀ epithelial฀ (A549)฀ cells฀ at฀ 1.25฀µM฀446 
compound฀ concentration,฀ and฀ identified฀ Nelfinavir,฀ Aminacrine,฀ Dequalinium฀ dichloride฀ and฀447 
Thonzonium฀bromide฀as฀hits฀ (Supplementary฀Table฀1).฀Nelfinavir฀ (CAS฀number฀159989-65-8),฀448 
hereafter฀ referred฀ to฀ as฀ Nelfinavir,฀ strongly฀ inhibited฀ plaque฀ numbers฀ at฀ nanomolar฀ concen-449 
trations,฀ comparable฀ to฀ the฀ known฀ HAdV฀ nucleoside฀ analogue฀ inhibitor฀ 3'-deoxy-3'-fluorothy-450 
midine฀ (DFT,฀ Figure฀ 1A,฀ 1B).฀ Dequalinium฀ dichloride,฀ Aminacrine฀ and฀ Thonzonium฀ bromide฀451 
were฀excluded฀from฀further฀analyses฀due฀to฀toxicity฀(100),฀and฀potential฀mutagenic฀effects฀(131).฀452 
Long-term฀ incubations฀ of฀ uninfected฀ A549฀ cells฀ with฀ Nelfinavir฀ up฀ to฀ 115฀ h฀ showed฀ median฀453 
toxicity฀TC50฀of฀25.7฀µM,฀as฀determined฀by฀cell฀ impedance฀measurements฀using฀xCELLigence฀454 
(Figure฀ 1C).฀ xCELLigence฀ measures฀ the฀ impedance฀ of฀ electrical฀ currents฀ imposed฀ by฀ cell฀455 
adherence฀ to฀gold-plated฀microelectrodes฀ implanted฀ in฀ culture฀wells.฀ Impedance฀ is฀expressed฀456 
as฀ cell฀ index฀ (CI),฀ a฀ unitless฀ parameter฀ proportional฀ to฀ the฀ cell฀ number,฀ cell฀ size,฀ and฀ cell฀457 
adherence.฀ For฀ raw฀ CI฀ profiles,฀ see฀ Supplementary฀ Figure฀ 1A.฀ CI฀ measurements฀ were฀458 
consistent฀ with฀ presto-blue฀ assays,฀ and฀ cell฀ numbers฀ determined฀ by฀ counting฀ nuclei฀459 
(Supplementary฀ Table฀ 1).฀ This฀ was฀ in฀ agreement฀ with฀ previous฀ reports,฀ and฀ acceptable฀ side฀460 
effects฀ in฀clinical฀use฀against฀HIV฀(102,฀132).฀The฀therapeutic฀ index฀50฀(TI50)฀of฀Nelfinavir฀was฀461 
27.1฀(Figure฀1D),฀as฀determined฀by฀the฀ratio฀between฀the฀concentration฀yielding฀50%฀loss฀of฀cell฀462 




Nelfinavir does not affect single round infection  467 
We฀first฀tested฀if฀Nelfinavir฀affected฀viral฀protein฀production.฀HAdV-C2-dE3B-GFP-infected฀A549฀468 
cells฀ were฀ analysed฀ for฀GFP฀ under฀ the฀ immediate฀ early฀ CMV฀ promoter,฀ and฀ the฀ late฀ protein฀469 
hexon฀expressed฀after฀viral฀DNA฀replication฀at฀46฀hours฀post฀infection฀(hpi).฀Results฀indicate฀that฀470 
Nelfinavir฀ had฀ no฀ effect฀ on฀GFP฀ or฀ hexon฀ expression฀ at฀ the฀ tested฀ concentrations,฀ while฀ the฀471 
formation฀ of฀ fluorescent฀ plaques฀ was฀ completely฀ inhibited฀ (Figure฀ 2A,฀ and฀ Figure฀ 1D).฀ This฀472 
result฀was฀in฀agreement฀with฀the฀notion฀that฀Nelfinavir฀did฀not฀affect฀the฀replication฀of฀the฀HAdV-473 
C5฀ genome,฀ as฀ determined฀ by฀ titration฀ of฀ cell-associated฀ infectious฀ particles฀ (133).฀We฀ next฀474 
examined฀if฀Nelfinavir฀affected฀the฀formation฀of฀viral฀particles.฀Transmission฀electron฀microscopy฀475 
(TEM)฀of฀HAdV-C2-dE3B-GFP-infected฀cells฀revealed฀large฀numbers฀of฀virions฀in฀the฀nuclei฀of฀476 
Nelfinavir-treated฀ and฀ untreated฀ cells฀ (Figure฀ 2B).฀ This฀ result฀ was฀ conforming฀ with฀ the฀477 















































There฀ was฀ no฀ evidence฀ for฀ increase฀ of฀ precursor฀ VI฀ or฀ VII฀ (pVI฀ or฀ pVII)฀ in฀ HAdV-C5฀ from฀483 
Nelfinavir-treated฀ cells,฀ in฀ contrast฀ to฀ temperature-sensitive฀ (ts)฀ 1฀ particles,฀ which฀ lack฀ the฀484 




Together,฀ these฀ results฀ indicate฀ that฀ Nelfinavir฀ does฀ not฀ affect฀ the฀ production฀ of฀ infectious฀489 
virions฀in฀single฀round฀infections.฀490 
฀491 
Nelfinavir inhibits HAdV-C egress 492 
We฀ investigated฀ the฀ kinetics฀ of฀ HAdV-C2-dE3B-GFP฀ production฀ and฀ the฀ release฀ to฀ the฀493 
supernatant.฀Supernatants฀and฀whole฀cell฀lysates฀of฀treated-฀and฀non-treated฀infected฀cells฀were฀494 





difference฀ in฀ infectious฀ load฀ was฀ confirmed฀ by฀ titration฀ of฀ supernatants฀ from฀ separate฀ time฀500 
course฀experiments฀at฀three฀different฀concentrations฀of฀Nelfinavir฀(Figure฀3B).฀At฀7฀dpi,฀a฀dosage฀501 





We฀next฀assessed฀ the฀potency฀of฀ the฀Nelfinavir฀against฀HAdV-C2฀ transmission฀by฀quantifying฀507 
the฀number฀of฀nuclei,฀which฀normally฀decreases฀due฀to฀ lytic฀virus฀replication.฀Nelfinavir฀(3฀µM)฀508 
robustly฀reduced฀the฀number฀of฀dead฀cells,฀and฀strongly฀reduced฀the฀number฀of฀infected฀cells฀up฀509 
to฀ 100฀ pfu฀ /฀ well฀ (Figure฀ 3D).฀ Remarkably,฀ HAdV-C2-dE3B-GFP฀ formed฀ delayed฀ plaques฀ in฀510 
presence฀of฀Nelfinavir,฀starting฀at฀4฀dpi฀(Figures฀3E,฀3F).฀These฀late฀plaques฀showed฀a฀strikingly฀511 
round฀ morphology,฀ which฀ was฀ calculated฀ to฀ be฀ significantly฀ different฀ from฀ the฀ comet-shaped฀512 
plaques฀ early฀ in฀ infection฀ of฀ control฀ cells฀ (Figure฀ 3G).฀ The฀ direction฀ of฀ the฀ comet฀ tail฀ of฀ lytic฀513 
plaques฀ can฀ be฀ aligned฀ by฀ tilting฀ of฀ the฀ incubation฀ plate฀ (72).฀ Thereby,฀ the฀ cell฀monolayer฀ is฀514 
positioned฀ non-orthogonally฀ to฀ the฀ vector฀ of฀ thermal฀ convection฀ flux฀ of฀ the฀ liquid฀ cell฀ culture฀515 
medium.฀While฀the฀direction฀of฀the฀comet-shaped฀plaques฀could฀be฀aligned฀using฀this฀method฀in฀516 
the฀ non-treated฀ infections,฀ the฀ late฀Nelfinavir฀ plaques฀ remained฀mostly฀ round฀ (Supplementary฀517 
Figures฀2A-C).฀Moreover,฀ there฀was฀no฀correlation฀between฀ the฀size฀of฀ the฀plaques฀and฀ their฀518 
roundness฀ irrespective฀of฀Nelfinavir฀up฀ to฀7฀dpi,฀demonstrating฀ that฀ the฀ round฀plaques฀did฀not฀519 
change฀morphology฀over฀ time฀ (Supplementary฀ Figure฀ 2D).฀Collectively,฀ the฀ data฀ indicate฀ that฀520 
virus฀transmission฀in฀presence฀of฀Nelfinavir฀is฀not฀driven฀by฀the฀bulk฀current฀of฀cell฀free฀medium.฀฀521 
฀522 
HAdV inhibition by Nelfinavir depends on ADP  523 












































C2-dE3B-GFP฀ mutant,฀ HAdV-C2-dE3B-GFP-dADP.฀ The฀ mutant฀ completely฀ lacks฀ ADP฀526 
expression,฀as฀indicated฀by฀immunofluorescence฀and฀Western฀blot฀experiments฀(Supplementary฀527 
Figure฀3A,฀3B).฀HAdV-C2-dE3B-GFP-dADP฀ formed฀particles฀ indistinguishable฀ from฀HAdV-C2-528 
dE3B-GFP,฀ as฀ indicated฀ by฀ negative฀ stain฀ EM฀ (Supplementary฀ Figure฀ 3C).฀ HAdV-C2-dE3B-529 
GFP-dADP฀showed฀a฀delayed฀onset฀of฀plaque฀ formation฀by฀about฀1฀day,฀compared฀ to฀HAdV-530 
C2-dE3B-GFP฀(Figure฀4A).฀These฀data฀are฀in฀agreement฀with฀previous฀kinetic฀studies฀with฀the฀531 
ADP฀ deletion฀ mutant฀ HAdV-C฀ dl712฀ (107)฀ (see฀ also฀ Supplementary฀ Figure฀ 3A).฀ HAdV-C2-532 
dE3B-GFP-dADP฀plaques฀were฀comet-shaped,฀albeit฀ their฀ comet-heads฀appeared฀bigger฀and฀533 
more฀dense฀(Figure฀4A).฀While฀the฀parental฀virus฀was฀highly฀sensitive฀to฀Nelfinavir,฀HAdV-C2-534 
dE3B-GFP-dADP฀ required฀much฀higher฀ concentrations฀of฀ the฀compound฀ to฀ show฀ inhibition฀of฀535 
plaque฀ formation฀ (Figure฀ 4B,฀ Supplementary฀ Table฀ 2).฀ In฀ accordance,฀ the฀ ADP-deleted฀ virus฀536 
induced฀ cell฀ death฀ independent฀ of฀ Nelfinavir,฀ unlike฀ the฀ ADP-expressing฀ virus,฀ as฀ concluded฀537 
from฀cell฀impedance฀measurements฀with฀xCELLigence฀(Figure฀4C,฀Supplementary฀Figures฀3D,฀538 
3E).฀Finally,฀HAdV-C2-dE3B-GFP-dADP฀exhibited฀a฀strongly฀diminished฀separation฀of฀anti-viral฀539 
efficacy฀ from฀ toxicity,฀as฀ indicated฀by฀ reduced฀TI50฀ values฀ compared฀ to฀ the฀parental฀ virus,฀ for฀540 
example฀2.1฀versus฀66.8฀with฀A549฀cells,฀8.9฀versus฀61.0฀with฀HeLa฀cells,฀and฀4.6฀versus฀55.2฀541 
with฀ HBEC฀ cells฀ (Figure฀ 4D).฀ These฀ effects฀ were฀ in฀ agreement฀ with฀ similar฀ experiments฀542 
performed฀with฀the฀previously฀described฀ADP-knock฀out฀mutant฀dl712฀and฀the฀parental฀rec700,฀543 
an฀HAdV-C5/2฀hybrid฀ virus฀ (135,฀ 136).฀The฀data฀are฀ shown฀ in฀ (Supplementary฀Figures฀3F฀ to฀544 
3H).฀Together,฀the฀results฀show฀that฀the฀selective฀antiviral฀effects฀of฀Nelfinavir฀are฀more฀cell-type฀545 
dependent฀ in฀case฀of฀HAdV฀ lacking฀ADP฀ than฀ in฀ADP-expressing฀viruses,฀and฀ the฀effects฀are฀546 
comparatively฀small฀for฀viruses฀lacking฀ADP.฀฀547 
฀548 
Finally,฀ we฀ performed฀ immunofluorescence฀ experiments฀ with฀ HAdV-C2-dE3B-GFP-infected฀549 
A549฀cells฀at฀44฀hpi฀(Figure฀4E).฀Under฀non-perturbed฀conditions,฀ADP฀accumulated฀in฀cytoplas-550 
mic฀foci฀and฀the฀nuclear฀envelope.฀Nelfinavir฀treatment฀did฀not฀affect฀the฀overall฀ADP฀expression฀551 
levels฀ nor฀ the฀ amount฀ of฀ ADP฀ in฀ the฀ nuclear฀ periphery,฀ including฀ the฀ nuclear฀ envelope,฀ but฀552 
completely฀ abolished฀ the฀ cytoplasmic฀ ADP฀ foci฀ as฀ indicated฀ by฀ granularity฀ quantifications฀553 
(Figure฀ 4E,฀ right฀ graph).฀ Intriguingly,฀ Tollefson฀ and฀ co-workers฀ observed฀ earlier฀ that฀ ADP฀554 











lytic฀ infected฀ cell฀ (staining฀ PI-positive)฀ yields฀ comet-shaped฀ infection฀ foci฀ due฀ to฀ convective฀566 
passive฀mass฀ flow฀ in฀ the฀cell฀culture฀medium฀(72,฀101),฀consistent฀with฀ lytic฀HAdV-C฀ infection฀567 














































To฀ test฀ if฀ round-shaped฀ infection฀ foci฀ (plaques)฀ occurred฀ in฀ regular฀ HAdV-C2-dE3B-GFP฀572 
infections,฀we฀analysed฀A549฀cells฀infected฀with฀less฀than฀one฀plaque฀forming฀unit฀(pfu)฀per฀well฀573 
in฀160฀wells฀up฀to฀8฀dpi.฀Thirty฀three฀wells฀developed฀a฀single฀plaque.฀Twenty฀four฀of฀them฀were฀574 
fast฀ emerging฀ comet-shaped฀ plaques,฀ of฀ which฀ the฀ donor฀ cell฀ (indicated฀ by฀ the฀ pink฀ arrow),฀575 
disappeared฀between฀2฀and฀3฀dpi฀ (Figure฀5C,฀upper฀panel).฀ In฀contrast,฀nine฀wells฀developed฀576 
delayed฀ round฀plaques฀starting฀6฀dpi฀ (Figure฀5D,฀ lower฀panel).฀ In฀all฀ these฀cases,฀ the฀original฀577 
infected฀cell฀(orange฀arrow)฀remained฀GFP-positive฀and฀apparently฀viable,฀and฀the฀surrounding฀578 
cells฀gradually฀became฀infected.฀These฀data฀suggest฀that฀HAdV-C2฀utilizes฀both฀lytic฀and฀non-579 
lytic฀ transmission,฀ the฀ former฀ involving฀ cell-free฀ transmission,฀ and฀ the฀ latter฀ cell-associated฀580 
transmission.฀฀581 
฀582 
Nelfinavir has a broad anti-HAdV spectrum 583 
We฀finally฀assessed฀the฀inhibition฀breadth฀of฀Nelfinavir฀against฀various฀HAdV฀types฀from฀species฀584 
A,฀B,฀C฀and฀D฀ in฀different฀human฀cell฀ lines,฀as฀well฀as฀mouse฀adenovirus฀ (MAdV)฀1฀and฀3฀ in฀585 
mouse฀ rectum฀ carcinoma฀ CMT93฀ cells.฀ To฀ balance฀ statistical฀ significance฀ and฀ automated฀586 
plaque฀ segmentation,฀ we฀ first฀ determined฀ the฀ optimal฀ amount฀ of฀ inoculum฀ and฀ duration฀ of฀587 
infection฀for฀each฀virus฀and฀cell฀line.฀The฀resulting฀TI50฀values฀of฀Nelfinavir฀were฀heterogeneous฀588 
for฀different฀HAdV฀types,฀as฀determined฀in฀A549฀cells฀(Figure฀6A,฀for฀details฀see฀Supplementary฀589 
Table฀ 2).฀While฀ all฀ the฀ tested฀ HAdV-C฀ types฀ as฀ well฀ as฀ HAdV-B14฀ showed฀ high฀ TI50s฀ (>10)฀590 
ranging฀from฀12.22฀(HAdV-C1)฀to฀71.09฀(HAdV-C2).฀Members฀of฀HAdV฀species฀A,฀D฀and฀most฀591 
of฀ the฀HAdV-B฀types฀showed฀intermediate฀(2฀ -฀10)฀to฀ low฀Nelfinavir฀susceptibility฀(<2),฀notably฀592 
HAdV-B7฀and฀B11฀with฀TI50<1.฀MAdV-1฀and฀3฀also฀showed฀low฀susceptibility.฀Noticeably,฀a฀high฀593 
susceptibility฀of฀HAdV-C฀was฀consistently฀observed฀in฀human฀lung฀epithelial฀carcinoma฀(A549)฀594 
cells,฀ human฀ epithelial฀ cervix฀ carcinoma฀ (HeLa)฀ cells,฀ immortalized฀ primary฀ normal฀ human฀595 
corneal฀epithelial฀ (HCE)฀cells฀as฀well฀as฀normal฀human฀bronchial฀epithelial฀ (HBEC)฀cells.฀The฀596 
corresponding฀ TI50฀ values฀ were฀ in฀ the฀ same฀ range฀ as฀ for฀ herpes฀ simplex฀ virus฀ (HSV)฀ 1,฀ for฀597 
which฀Nelfinavir฀was฀reported฀to฀be฀an฀egress฀inhibitor฀(133,฀138,฀139).฀฀598 
฀599 
We฀ finally฀ examined฀ the฀ plaque฀morphologies฀ in฀ non-perturbed฀ infections฀ by฀ immunofluores-600 
cence฀ staining฀ of฀ the฀ late฀ proteins฀VI฀ and฀hexon,฀ as฀well฀ as฀macroscopic฀ analyses฀of฀ crystal฀601 
violet฀stained฀dishes฀ for฀classical฀plaques฀ (Figure฀6B).฀Viruses฀ that฀were฀highly฀susceptible฀ to฀602 
Nelfinavir฀ (exhibiting฀high฀TI50฀values)฀ formed฀exclusively฀comet-shaped฀plaques.฀Viruses฀with฀603 
low฀ TI50฀ values,฀ such฀ as฀ A31,฀ B11฀ or฀ D37฀ had฀ a฀ high฀ fraction฀ of฀ round฀ plaques,฀ even฀when฀604 
infected฀with฀more฀than฀1฀pfu฀/฀well.฀This฀demonstrates฀that฀the฀slowly฀growing฀round฀infection฀605 
foci฀observed฀in฀fluorescent฀microscopy฀gave฀similarly฀shaped฀lesions฀due฀to฀cytotoxicity,฀akin฀to฀606 

















































A฀ phenotypic฀ screen฀ of฀ the฀ PCL฀ identified฀ Nelfinavir฀ as฀ a฀ potent,฀ post-exposure฀ inhibitor฀ of฀614 
HAdV-C2-dE3B-GFP฀plaque฀formation฀in฀cell฀culture฀(100).฀Nelfinavir฀is฀a฀non-nucleoside฀class฀615 
inhibitor฀ against฀ a฀ range฀ of฀ HAdV฀ types.฀ Surprisingly,฀ we฀ found฀ Nelfinavir฀ to฀ inhibit฀ HAdV฀616 
infection,฀ although฀ Nelfinavir฀ was฀ previously฀ classified฀ as฀ inactive฀ against฀ HAdV-C฀ based฀ on฀617 
replication฀assays฀ (133).฀ It฀ is฀ the฀off-patent฀FDA-approved฀active฀pharmaceutical฀ ingredient฀of฀618 
Viracept.฀Nelfinavir฀was฀originally฀developed฀as฀an฀inhibitor฀against฀the฀HIV฀aspartyl฀protease.฀It฀619 
is฀ orally฀ bioavailable,฀with฀ an฀ inhibitory฀ concentration฀ in฀ the฀ low฀nanomolar฀ range฀ (102,฀ 132).฀620 
Nelfinavir฀ inhibits฀ the฀ replication฀ of฀ enveloped฀ viruses,฀ including฀ SARS฀ coronavirus฀ (140),฀621 
hepatitis฀C฀virus฀(141)฀as฀well฀as฀α-,฀β-฀and฀γ-herpes฀viruses฀(133).฀In฀the฀case฀of฀the฀α-herpes฀622 
virus฀ HSV-1,฀ Nelfinavir฀ inhibits฀ the฀ envelopment฀ of฀ the฀ capsid฀ with฀ cytoplasmic฀ membranes.฀623 
This฀ coincided฀ with฀ impaired฀ glycosylation฀ of฀ gB฀ and฀ gC฀ in฀ the฀ TGN฀ (133,฀ 138,฀ 139,฀ 142).฀624 
Nelfinavir฀was฀reported฀to฀inhibit฀the฀activity฀of฀regulatory฀proteases฀in฀the฀Golgi,฀the฀growth฀of฀625 
cancer฀ cells฀ and฀ to฀ induce฀ a฀ wealth฀ of฀ other฀ effects,฀ including฀ autophagy,฀ ER฀ stress,฀ the฀626 
unfolded฀ protein฀ response,฀ and฀ apoptosis฀ (143–149)฀ (150–152,฀ reviewed฀ in฀ 153–155).฀ It฀627 
remains฀ unknown฀ if฀ Nelfinavir฀ exerts฀ these฀ pleiotropic฀ effects฀ by฀ interfering฀ with฀ diverse฀628 
processes฀or฀a฀particular฀one.฀฀629 
฀630 




transmission฀gave฀ rise฀ to฀symmetric฀ round-shaped฀plaques.฀Nelfinavir฀ specifically฀suppressed฀635 
the฀ lytic฀ spread฀of฀HAdV,฀most฀ prominently฀ the฀HAdV-C฀ types฀and฀B14,฀ but฀ not฀ other฀HAdV,฀636 





due฀ to฀ the฀ lack฀of฀specific฀assays฀and฀ inhibitors.฀Single฀cell฀analyses฀combined฀with฀machine฀642 
learning฀start฀to฀identify฀specific฀features฀of฀lytic฀cells,฀such฀as฀increased฀intra-nuclear฀pressure฀643 
compared฀ to฀ non-lytic฀ cells฀ (158).฀ The฀ lysis฀ induced฀ by฀ HAdV฀ was฀ suggested฀ to฀ involve฀644 
caspase-dependent฀functions,฀and฀necrosis-like฀features฀(99,฀159,฀160).฀The฀best฀characterized฀645 
factor฀ in฀HAdV฀cell฀ lysis฀is฀ADP,฀a฀small฀membrane฀protein฀encoded฀in฀HAdV-C฀(90,฀91,฀161).฀646 
ADP-deletion฀mutants฀show฀delayed฀onset฀of฀plaque฀formation฀(73,฀135).฀Lysis฀is฀enhanced฀by฀647 
increased฀ADP฀levels฀and฀tuned฀by฀post-translational฀ADP฀processing฀(73,฀74,฀135).฀ADP฀has฀a฀648 
single฀ signal/anchor฀ sequence,฀ and฀ its฀ lumenal฀ domain฀ is฀ N-฀ and฀ O-glycosylated.฀ The฀ N-649 
terminal฀segment฀is฀cleaved฀off฀in฀the฀Golgi฀lumen,฀and฀the฀membrane-anchored฀ADP฀localizes฀650 
















































virus฀E1฀and฀E2,฀ as฀well฀ as฀ viroporin-mediated฀membrane฀permeabilization,฀ including฀mouse฀657 
hepatitis฀ virus฀E฀protein,฀SARS-CoV-1฀E฀protein฀and฀sindbis฀virus฀6K.฀For฀ reviews,฀see฀ (163,฀658 
164).฀659 
฀660 
Conspicuously,฀ the฀cell฀ lysis฀defective฀HAdV฀mutant฀pm734.4฀encodes฀a฀C2฀mutant฀ADP฀with฀661 
two฀ point฀ mutations฀ in฀ the฀ transmembrane฀ domain,฀ C53R฀ and฀ M56L฀ (107).฀ The฀ mutant฀ ADP฀662 
localizes฀ to฀ the฀ER฀and฀ the฀nuclear฀envelope,฀but฀not฀ the฀Golgi,฀unlike฀ the฀parental฀wild฀ type฀663 
virus฀rec700.฀The฀localization฀of฀the฀pm734.4฀ADP฀is฀akin฀to฀the฀localization฀of฀HAdV-C2฀ADP฀in฀664 
Nelfinavir-treated฀cells,฀which฀resist฀ lysis฀and฀lack฀ADP฀localization฀in฀the฀Golgi.฀We฀speculate฀665 
that฀ the฀ palmitoylation฀ of฀ ADP฀ in฀ the฀ Golgi฀ is฀ crucial฀ for฀ ADP฀ to฀ enhance฀ the฀ rupture฀ of฀ the฀666 
nuclear฀ membrane฀ in฀ lytic฀ HAdV-C฀ egress.฀ Nelfinavir฀ may฀ interfere฀ with฀ ADP฀ palmitoylation฀667 
either฀by฀ inhibiting฀a฀palmitoyl-acyltransferase฀or฀by฀dispersing฀ the฀donor฀substrate฀ for฀protein฀668 
palmitoylation,฀palmitoyl-coenzyme฀A฀(164).฀Remarkably,฀Nelfinavir฀has฀a฀high฀ logP฀value,฀4.1฀669 
to฀4.68฀(165,฀166),฀and฀partitions฀into฀lipophilic฀domains฀of฀the฀cell,฀including฀membranes.฀This฀670 
is฀ akin฀ to฀ another฀ lipophilic฀ drug฀ with฀ pleiotropic฀ effects,฀ the฀ anti-viral฀ and฀ anti-helminthic฀671 
compound฀Niclosamide,฀which฀ is฀ a฀weak฀acid฀and฀acts฀as฀a฀protonophore฀extracting฀protons฀672 





type฀(169–171).฀This฀ is฀ in฀agreement฀with฀ the฀observation฀ that฀HAdV฀types฀of฀ the฀A,฀B฀and฀D฀678 
species฀ form฀ comet-shaped฀ plaques,฀ and฀ that฀ ADP-deleted฀HAdV-C2฀ lyse฀ the฀ host฀ cell,฀ and฀679 
form฀comet-shaped฀plaques,฀albeit฀delayed฀and฀with฀lower฀efficacy฀than฀ADP-containing฀rec700฀680 
or฀ HAdV-C2-dE3B-GFP.฀ Conspicuously,฀ other฀ AdV฀ proteins฀ besides฀ ADP฀ were฀ reported฀ to฀681 
interfere฀ with฀ cell฀ lysis,฀ such฀ as฀ the฀ early฀ region฀ 4฀ ORF4฀ protein,฀ which฀ induces฀ nuclear฀682 
envelope฀ blebbing฀ and฀ promotes฀ the฀ loss฀ of฀ nuclear฀ integrity฀ (172,฀ 173).฀ This,฀ together฀ with฀683 
diverse฀ cellular฀ mechanisms฀ underlying฀ force฀ generation฀ and฀ membrane฀ rupture,฀ could฀684 
compensate฀for฀the฀lack฀of฀ADP฀in฀some฀forms฀of฀lytic฀virus฀egress฀(51,฀55,฀173).฀We฀consider฀it฀685 
unlikely฀ that฀genetic฀variability฀of฀ the฀ inoculum฀accounts฀ for฀ the฀presence฀of฀ lytic฀and฀non-lytic฀686 




tive฀ non-lytic฀ HAdV฀ transmission฀ pathway,฀ which฀ gives฀ rise฀ to฀ slow-growing฀ symmetrical฀691 
plaques.฀This฀non-lytic฀pathway฀exists฀in฀unperturbed฀cells,฀but฀is฀camouflaged฀by฀the฀rapid฀and฀692 
















































of฀ large฀ RNPs฀ in฀ Drosophila,฀ and฀ perhaps฀ similar฀ to฀ HSV฀ budding฀ (174,฀ 175).฀ Cytoplasmic฀699 
membrane฀ budding฀ could฀ be฀ enhanced฀ by฀ the฀ ESCRT฀ complex,฀ which฀ is฀ known฀ to฀ release฀700 
enveloped฀ viruses,฀ such฀ as฀ HIV,฀ and฀ also฀ facultative-enveloped฀ viruses,฀ such฀ as฀ hepatitis฀ A฀701 
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Figure 1: The small molecule Nelfinavir is a potent inhibitor of HAdV-C infection.  769 
 770 
A Representative 384-well epifluorescence microscopy images of cells treated with DMSO (left), 771 
Nelfinavir (centre) and DFT (right), infected with HAdV-C2-dE3B-GFP for 72 h. Hoechst-stained nuclei are 772 
shown in blue, viral GFP in green. Dotted lines indicate well outline. Scale bar is 5 mm.  773 
B Structural formula of Nelfinavir mesylate.  774 
C The half-maximal toxicity (TC50) in uninfected A549 cells was determined by Nelfinavir dose-response 775 
impedance measurements at different times of drug treatment. The x-axis indicates the time post cell 776 
seeding, as well as drug addition.  Impedance was recorded at intervals of 15 min using xCELLigence 777 
reporting on the cell number and cell adhesion to the electrode-coated wells. The raw CI data are 778 
available in Supplementary Figure 1.  779 
D Separation of effect (EC50, plaque numbers) and toxicity (TC50, nuclei numbers) of Nelfinavir in A549 780 
cells at 82 hpi based on four technical replicates. Plaque numbers per well are depicted as red circles, 781 
and numbers of infected nuclei as green circles. Numbers of nuclei in Nelfinavir-treated, uninfected wells 782 











































Figure 2. Nelfinavir does not affect early or late steps of HAdV-C infection.  784 
 785 
A No effect of Nelfinavir on the expression of CMV-GFP (green) or the late viral protein hexon (red) in 786 
HAdV-C2-dE3B-GFP-infected A549 cells. Data points represent for each of the four biological replicates: 787 
mean median, nuclear intensities per well normalized to the mean median nuclear intensities of the 788 
DMSO-treated wells. Epifluorescence microscopy images were segmented and analysed using 789 
CellProfiler.  790 
B Representative TEM images of late stage HAdV-C2-dE3B-GFP-infected A549 cells at 41 hpi reveal 791 
viral particles inside the nucleus in both DMSO-treated and Nelfinavir-treated cells (white arrow head). 792 
Black arrow heads indicate the nuclear envelope, arrow head with * points to rupture. Scale bar 793 
equivalent to 2 µm.  794 
C Nelfinavir does not affect the maturation of HAdV-C5, as indicated by fully processed VI and VII 795 
proteins in purified particles grown in presence of Nelfinavir. Note that HAdV-C2-ts1 lacking the L3/p23 796 
protease contains the precursor capsid proteins of VI and VII (pVI and pVII). 797 
D HAdV-C5 grown in presence of Nelfinavir (HAdV-C5+Nelfinavir) binds to naive A549 cells similar as HAdV-798 
C5 from control cells. Cells were incubated with virus at 4°C for 1 h and fixed with PFA. Staining of viral 799 
capsids with an α-hexon antibody (green puncta). Nuclei shown with Hoechst staining (blue). Cells were 800 
visualized by NHS-ester staining (red). Images are max projections of confocal z stacks, and also show 801 
zoomed in views (grey squares). Scale bars = 20 µm.  802 
E Particles produced in presence of Nelfinavir are fully infectious. A549 cells were inoculated with purified 803 
HAdV-C5 and incubated in absence (grey) or presence of Nelfinavir (orange colors) for 44 hpi. Infection 804 
analyses by α-hexon immunofluorescence staining, and cell numbers derived from Hoechst staining 805 












































Figure 3. Nelfinavir is a post-exposure inhibitor of HAdV-C egress.  808 
 809 
A A549 cells were imaged at 3 days post inoculation with 1:10 diluted cell lysates (left) or supernatants 810 
(right) from Nelfinavir or control A549 cells, which had been infected with HAdV-C2-dE3B-GFP for the 811 
indicated times (harvested hpi). Results show delayed viral progeny release to the supernatant of 812 
Nelfinair-treated cells. Nuclei are shown in blue, infection marker in green (GFP).  813 
B Released and cell-associated progeny from HAdV-C2-dE3B-GFP-infected A549 cells treated with 814 
Nelfinavir (orange) or DMSO (green), as determined by titration on A549 cells in a 12-well assay format. 815 
Lines indicate mean slopes, dotted lines standard error. Linear regression of three biological triplicates.   816 
C Time-resolved emergence of plaques in HAdV-C2-dE3B-GFP-infected A549 cells treated with 1.25 µM 817 
Nelfinavir. Plaques in infected, non-treated wells are shown in green, Nelfinavir-treated wells in orange 818 
and nuclei in blue. Data points represent one of eight technical replicates. Coloured vertical lines indicate 819 
means and error bars the standard deviations.  820 
D The inhibitory effect of Nelfinavir on HAdV-C2-dE3B-GFP spread is dependent on the amount input 821 
virus during initial infection. Number of infected, GFP-positive cells shown in green at 3 µM Nelfinavir 822 
relative to the mean infection of solvent-treated cells infected with the corresponding dosage. Total 823 
number of nuclei shown in blue, number of PI-positive dead cells in red. Note that the number of infected 824 
cells at 43 hpi is not affected by the Nelfinavir treatment. Data points represent means of four technical 825 
replicates. Dotted lines indicate standard deviation.  826 
E Treatment of HAdV-C2-dE3B-GFP-infected A549 cells with 1.25 µM Nelfinavir suppresses comet-827 
shaped plaques and reveals slow growing quasi-round plaques. Viral GFP expression levels are shown 828 
as 16-color LUT. Scale bar is 1 mm.  829 
F Treatment with 1.25 µM Nelfinavir inhibits HAdV-C2-dE3B-GFP infection of A549 cells by slowing 830 
plaque formation. The numbers of infected cells and plaques per well of DMSO-treated wells are shown 831 
in green, those of Nelfinavir-treated wells in orange. Data points represent means of 24 technical 832 
replicates, including the well shown in the micrographs of panel D. Error bars indicate standard deviation. 833 
Statistical significance of drug versus non-treated cells was derived by the Kolmogorov-Smirnov test, p 834 
value < 0.0001 (****).  835 
G The delayed HAdV-C2-dE3B-GFP plaques in presence of 1.25 µM Nelfinavir are significantly rounder 836 
than control plaques, as indicated by Kolmogorov-Smirnov test. Data points indicate plaque regions in the 837 
well centre harbouring a single peak region. Summary of 24 technical replicates including the well shown 838 
in the micrographs of panel D. Regions consisting of at least 5 infected cells (≥1,500 µm2) were 839 
considered as a plaque. Plaque morphologies in control wells could not be quantified later than 3 dpi due 840 
to rapid virus dissemination. Plaques from DMSO-treated cells 3 dpi compared to Nelfinavir-treated ones 841 
5 dpi: approximate p value < 0.0001 (****). DMSO-treated plaques 3 dpi vs. Nelfinavir-treated plaques 6 842 











































Figure 4. ADP contributes to the inhibitory effect of Nelfinavir against HAdV-C.  844 
 845 
A The deletion of ADP from HAdV-C2-dE3B-GFP delays plaque formation in A549 cells by one day, but 846 
does not change plaque shape. Cells were infected with 1.1*105 VP / well. GFP is in green, hexon 847 
staining red, Hoechst signal of nuclei blue. Scale bar is 1 mm.  848 
B The deletion of ADP from HAdV-C2-dE3B-GFP reduces the antiviral effects of Nelfinavir in A549, with 849 
EC50 = 5.82 compared to 0.22 µM for the parental virus. HAdV-C2-dE3B-GFP infection was quantified at 850 
72 hpi, and 96 hpi for the ADP deletion mutant. Plaque numbers per well were normalized to the mean 851 
DMSO control and depicted as full green triangles for HAdV-C2-dE3B-GFP and empty red triangles for 852 
the ADP deletion mutant. Nuclei numbers of non-infected, treated wells were normalized to the mean 853 
DMSO control and depicted as full blue circles (72 h incubation), and empty blue circles (96 h). Data 854 
points represent means of four technical replicates. Error bars indicate standard deviation. EC50 values 855 
were derived from non-linear curve fitting. For detailed information and statistics, see Supplementary 856 
Table 2.  857 
C The delay of dell death was calculated from the highest mean cell index (CI) and its half maximum for 858 
each treatment (mean of two technical replicates). HAdV-C2-dE3B-GFP data in green and dADP in red. 859 
For HAdV-C2-dE3B-GFP-infected A549 treated with 25 µM Nelfinavir, the measurement was aborted due 860 
to overgrowth causing cytotoxicity before the maximal cell index was reached. Treatment with 100 µM 861 
Nelfinavir was toxic.  862 
D Therapeutic index (TI50) derived from the ratio of Nelfinavir concentration causing 50% toxicity (TC50) 863 
and the concentration leading to 50% reduction in plaque numbers per well (EC50). Results from different 864 
cancer and primary cells are shown for HAdV-C2-dE3B-GFP and HAdV-C2-dE3B-dADP lacking ADP. For 865 
detailed information and statistics, see Supplementary Table 2. 866 
E Representative high-magnification confocal images of HAdV-C2-dE3B-GFP-infected A549 cells 44 hpi 867 
showing the effect of Nelfinavir on ADP localization (left panel). ADP was stained by immunofluorescence 868 
with a rabbit α-HAdV-C2-ADP87-101 antibody (red). Cells were stained using NHS-ester (grey scale). White 869 
arrow heads highlight infected cells. Nuclei (blue), viral GFP (green). Images are max projections of 30 z 870 
planes with 0.5 µm z steps. Scale bar 10 µm. Relative units (RU) of total ADP expression (grey), 871 
localization to the nuclear rim (blue) and granularity (red) normalized to the mean values from DMSO 872 
control cells (right panel). The data set is comprised of 20 Nelfinavir-treated infected cells, and 23 control 873 
cells. Solid lines indicate median, dotted lines the 5-95% quantile. Kolmogorov-Smirnov indicated an ADP 874 











































Figure 5: Round plaque phenotypes in presence of neutralising anti-HAdV-C2 antibodies and in 876 
unperturbed HAdV-C2 infections. 877 
 878 
A Schematic overview of pathogen transmission routes in cell cultures. Cell lysis kills the donor cell and 879 
releases progeny, while non-lytic egress preserves the infected donor cell. Convection in the media leads 880 
to long-distance, comet-shaped plaques, and cell-free virus transmission is susceptible to neutralizing 881 
antibodies. In contrast, direct cell-to-cell spread of virus gives rise to symmetric slow growing plaques, 882 
resistant to neutralizing antibodies. Non-infected cells are shown in grey and nuclei in blue. First round 883 
infected cells are shown in dark green, nuclei with a ruptured envelope in red. Second round infected 884 
cells are shown in light green. Grey arrow represents direction of convective flow. Axes indicate side or 885 
top-down views.  886 
B Inhibition of cell-free HAdV-C2-dE3B-GFP transmission by an anti-HAdV-C2/5-neutralizing serum. 887 
Nuclei are shown in blue, viral GFP in green.  888 
C Infection of A549 cells with limiting amounts of HAdV-C2-dE3B-GFP (<1 pfu/ well, 9-75 VP/ well) in 160 889 
wells gives rise to 33 single plaques / well. Twenty-four wells contained GFP-positive comet-shaped 890 
plaques (upper panel), and nine developed delayed round plaques (lower panel). Dashed coloured 891 
squares indicate magnified regions of first-round infected cell below. Infected cell leading to comet-892 
shaped plaque (upper panel, pink arrow) lyses at 3 dpi as indicated by loss of GFP signal. Infected cell 893 











































Figure 6: Susceptibility of HAdV to Nelfinavir correlates with plaque shape.  895 
 896 
A Therapeutic index (TI50) calculated from the ratio of Nelfinavir concentration causing 50% toxicity (TC50) 897 
and the concentration leading to 50% plaque reduction (EC50). Different HAdVs, mouse adenoviruses 898 
(MAdV) and herpes simplex virus 1 (HSV-1) were tested in different cancer and primary cell lines. For 899 
detailed information and statistics, see Supplementary Table 2.  900 
B Representative microscopic and macroscopic plaque morphologies of Nelfinavir-sensitive and 901 
insensitive HAdV types. Grey scale images show plaques based on epifluorescence microscopy of hexon 902 
immunostaining or GFP expression in A549 cells (96 well format). Scale bar is 1 mm. Coloured images 903 
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